ArticleJournal of family medicine and primary care2026
Delayed diagnosis of metastatic melanoma reoccurrence: Case report.
Article in Journal of family medicine and primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes a 72-year-old patient with delayed diagnosis of metastatic melanoma reoccurrence. The original case of melanoma was excised from his left knee, arm, and torso in 2012. 2016 found the patient with metastatic melanoma biopsy positive to his back, to which the patient trialed pembrolizumab therapy but was unable to tolerate the gastrointestinal side effects. 2019 saw another reoccurrence of metastatic melanoma with CT CAP positive left inguinal lymphadenopathy and MRI positive intraosseous mass of the left calcaneus, both biopsy-proven melanoma. Due to these findings, the patient was started on encorafenib and binimetinib April of 2019, and by December of 2019, PET scan showed near complete resolution of the mass. Prior to seeing a new PCP, the patient attested that the leg growth had occurred and been increasing in size for 6 months. His oncologist did not comment on the nodular lesion at any point in his notes from visits during the same 6-month period, and a prior ER physician prescribed doxycycline to treat presumed cellulitis versus malignancy. The current PCP sent the patient for CT of the left leg in November of 2023; the patient was then sent to his oncologist where FNA was performed and supported the diagnosis of metastatic melanoma. Verily, this case report brings light to the notion that providers should have a high degree of suspicion of metastasis in patients such as this one and not delay definitive diagnosis, especially when there are obvious cutaneous manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.